Seven young boys given Bluebird's Skysona later developed blood cancers, findings that could shape how doctors balance the gene therapy’s risks against its benefit.
Eric Joseph has given his Hold rating due to a combination of factors surrounding Bluebird Bio’s portfolio and financial outlook. The recent publication in the New England Journal of Medicine ...